nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—osteoarthritis—Prednisone—systemic scleroderma	0.466	1	CpDpCtD
Celecoxib—ALB—Captopril—systemic scleroderma	0.0371	0.192	CbGbCtD
Celecoxib—ABCC4—Methotrexate—systemic scleroderma	0.0316	0.164	CbGbCtD
Celecoxib—ALB—Mycophenolate mofetil—systemic scleroderma	0.0292	0.151	CbGbCtD
Celecoxib—CYP2C9—Leflunomide—systemic scleroderma	0.0255	0.132	CbGbCtD
Celecoxib—CA5B—cervicothoracic ganglion—systemic scleroderma	0.0239	0.363	CbGeAlD
Celecoxib—ALB—Prednisone—systemic scleroderma	0.0233	0.121	CbGbCtD
Celecoxib—CYP2D6—Captopril—systemic scleroderma	0.0183	0.0946	CbGbCtD
Celecoxib—ALB—Methotrexate—systemic scleroderma	0.0117	0.0606	CbGbCtD
Celecoxib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00915	0.0474	CbGbCtD
Celecoxib—CYP2C9—cardial valve—systemic scleroderma	0.00788	0.119	CbGeAlD
Celecoxib—CYP3A4—Prednisone—systemic scleroderma	0.00731	0.0379	CbGbCtD
Celecoxib—MAPK14—blood vessel—systemic scleroderma	0.00279	0.0424	CbGeAlD
Celecoxib—PTGS2—skeletal joint—systemic scleroderma	0.00246	0.0374	CbGeAlD
Celecoxib—PDPK1—digestive system—systemic scleroderma	0.00193	0.0293	CbGeAlD
Celecoxib—PDPK1—lung—systemic scleroderma	0.00162	0.0245	CbGeAlD
Celecoxib—MAPK14—connective tissue—systemic scleroderma	0.00143	0.0217	CbGeAlD
Celecoxib—MAPK14—smooth muscle tissue—systemic scleroderma	0.00131	0.0199	CbGeAlD
Celecoxib—MAPK14—skin of body—systemic scleroderma	0.00129	0.0196	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00122	0.624	CbGdCrCtD
Celecoxib—CA12—connective tissue—systemic scleroderma	0.00109	0.0165	CbGeAlD
Celecoxib—CA9—digestive system—systemic scleroderma	0.00106	0.0161	CbGeAlD
Celecoxib—MAPK14—digestive system—systemic scleroderma	0.00103	0.0157	CbGeAlD
Celecoxib—PTGS2—artery—systemic scleroderma	0.00103	0.0156	CbGeAlD
Celecoxib—CA9—tendon—systemic scleroderma	0.00101	0.0153	CbGeAlD
Celecoxib—MAPK14—tendon—systemic scleroderma	0.000985	0.0149	CbGeAlD
Celecoxib—CA14—tendon—systemic scleroderma	0.000958	0.0145	CbGeAlD
Celecoxib—PTGS2—endothelium—systemic scleroderma	0.000871	0.0132	CbGeAlD
Celecoxib—MAPK14—lung—systemic scleroderma	0.000864	0.0131	CbGeAlD
Celecoxib—PTGS2—blood vessel—systemic scleroderma	0.000804	0.0122	CbGeAlD
Celecoxib—CA12—digestive system—systemic scleroderma	0.000785	0.0119	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000739	0.376	CbGdCrCtD
Celecoxib—CA5B—tendon—systemic scleroderma	0.00067	0.0102	CbGeAlD
Celecoxib—CA12—lung—systemic scleroderma	0.000656	0.00994	CbGeAlD
Celecoxib—CA5B—lung—systemic scleroderma	0.000588	0.00892	CbGeAlD
Celecoxib—CA2—connective tissue—systemic scleroderma	0.000558	0.00846	CbGeAlD
Celecoxib—ABCC4—digestive system—systemic scleroderma	0.000529	0.00802	CbGeAlD
Celecoxib—ORM1—lung—systemic scleroderma	0.00052	0.00789	CbGeAlD
Celecoxib—CA2—smooth muscle tissue—systemic scleroderma	0.00051	0.00774	CbGeAlD
Celecoxib—CA2—skin of body—systemic scleroderma	0.000504	0.00764	CbGeAlD
Celecoxib—ABCC4—tendon—systemic scleroderma	0.000503	0.00763	CbGeAlD
Celecoxib—CA4—digestive system—systemic scleroderma	0.000486	0.00737	CbGeAlD
Celecoxib—CA4—tendon—systemic scleroderma	0.000463	0.00701	CbGeAlD
Celecoxib—ABCC4—lung—systemic scleroderma	0.000442	0.0067	CbGeAlD
Celecoxib—PTGS2—connective tissue—systemic scleroderma	0.000412	0.00625	CbGeAlD
Celecoxib—CA4—lung—systemic scleroderma	0.000406	0.00615	CbGeAlD
Celecoxib—CA2—digestive system—systemic scleroderma	0.000403	0.00611	CbGeAlD
Celecoxib—CA2—tendon—systemic scleroderma	0.000384	0.00582	CbGeAlD
Celecoxib—PTGS2—smooth muscle tissue—systemic scleroderma	0.000377	0.00571	CbGeAlD
Celecoxib—PTGS2—skin of body—systemic scleroderma	0.000372	0.00564	CbGeAlD
Celecoxib—CYP2C9—digestive system—systemic scleroderma	0.000341	0.00517	CbGeAlD
Celecoxib—CA2—lung—systemic scleroderma	0.000337	0.0051	CbGeAlD
Celecoxib—PTGS2—digestive system—systemic scleroderma	0.000298	0.00451	CbGeAlD
Celecoxib—PTGS2—tendon—systemic scleroderma	0.000283	0.00429	CbGeAlD
Celecoxib—CYP3A4—digestive system—systemic scleroderma	0.00026	0.00394	CbGeAlD
Celecoxib—CYP2D6—digestive system—systemic scleroderma	0.000256	0.00388	CbGeAlD
Celecoxib—PTGS2—lung—systemic scleroderma	0.000249	0.00377	CbGeAlD
Celecoxib—MAPK14—Metabolism of mRNA—TNFSF13—systemic scleroderma	0.000197	0.00283	CbGpPWpGaD
Celecoxib—PDPK1—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000196	0.00282	CbGpPWpGaD
Celecoxib—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000193	0.00278	CbGpPWpGaD
Celecoxib—MAPK14—Endothelins—MMP1—systemic scleroderma	0.00019	0.00274	CbGpPWpGaD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.00019	0.00273	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000189	0.00272	CbGpPWpGaD
Celecoxib—MAPK14—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000185	0.00267	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000185	0.00267	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000184	0.00264	CbGpPWpGaD
Celecoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00018	0.00259	CbGpPWpGaD
Celecoxib—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.00018	0.00259	CbGpPWpGaD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000177	0.00255	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000174	0.0025	CbGpPWpGaD
Celecoxib—PDPK1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000174	0.0025	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—SELP—systemic scleroderma	0.000173	0.00248	CbGpPWpGaD
Celecoxib—MAPK14—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000172	0.00248	CbGpPWpGaD
Celecoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.000172	0.00248	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000171	0.00247	CbGpPWpGaD
Celecoxib—PDPK1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.00017	0.00244	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000169	0.00244	CbGpPWpGaD
Celecoxib—PDPK1—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000169	0.00244	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000169	0.00243	CbGpPWpGaD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000169	0.00243	CbGpPWpGaD
Celecoxib—MAPK14—Metabolism of RNA—TNFSF13—systemic scleroderma	0.000168	0.00242	CbGpPWpGaD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000166	0.00239	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by VEGF—NOS3—systemic scleroderma	0.000164	0.00236	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000162	0.00234	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—RHOB—systemic scleroderma	0.000161	0.00232	CbGpPWpGaD
Celecoxib—MAPK14—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000155	0.00223	CbGpPWpGaD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000154	0.00222	CbGpPWpGaD
Celecoxib—MAPK14—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000153	0.0022	CbGpPWpGaD
Celecoxib—MAPK14—Thromboxane A2 receptor signaling—NOS3—systemic scleroderma	0.000151	0.00218	CbGpPWpGaD
Celecoxib—MAPK14—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000151	0.00217	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000149	0.00215	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000148	0.00213	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—CSK—systemic scleroderma	0.000147	0.00211	CbGpPWpGaD
Celecoxib—MAPK14—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000142	0.00204	CbGpPWpGaD
Celecoxib—PDPK1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000139	0.00201	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—ITGAM—systemic scleroderma	0.000138	0.00199	CbGpPWpGaD
Celecoxib—MAPK14—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000133	0.00191	CbGpPWpGaD
Celecoxib—PDPK1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000132	0.0019	CbGpPWpGaD
Celecoxib—MAPK14—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000131	0.00188	CbGpPWpGaD
Celecoxib—MAPK14—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.00013	0.00187	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CSK—systemic scleroderma	0.000127	0.00183	CbGpPWpGaD
Celecoxib—MAPK14—FGF signaling pathway—MMP9—systemic scleroderma	0.000125	0.0018	CbGpPWpGaD
Celecoxib—PDPK1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000125	0.00179	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—CD247—systemic scleroderma	0.000124	0.00179	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—ITGAM—systemic scleroderma	0.000124	0.00179	CbGpPWpGaD
Celecoxib—MAPK14—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000122	0.00176	CbGpPWpGaD
Celecoxib—MAPK14—Leptin signaling pathway—NOS3—systemic scleroderma	0.00012	0.00173	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CD247—systemic scleroderma	0.000119	0.00172	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—IL1A—systemic scleroderma	0.000118	0.00171	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000116	0.00167	CbGpPWpGaD
Celecoxib—MAPK14—Platelet homeostasis—NOS3—systemic scleroderma	0.000116	0.00167	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000112	0.00161	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—BLK—systemic scleroderma	0.00011	0.00159	CbGpPWpGaD
Celecoxib—MAPK14—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000107	0.00153	CbGpPWpGaD
Celecoxib—MAPK14—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000105	0.00152	CbGpPWpGaD
Celecoxib—MAPK14—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.000105	0.00151	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000103	0.00148	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—SELP—systemic scleroderma	0.000102	0.00147	CbGpPWpGaD
Celecoxib—MAPK14—Leptin signaling pathway—IL1B—systemic scleroderma	0.000102	0.00147	CbGpPWpGaD
Celecoxib—MAPK14—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000102	0.00147	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000102	0.00147	CbGpPWpGaD
Celecoxib—MAPK14—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000102	0.00146	CbGpPWpGaD
Celecoxib—PDPK1—Disease—SMAD7—systemic scleroderma	0.000101	0.00145	CbGpPWpGaD
Celecoxib—CA14—Metabolism—HSPG2—systemic scleroderma	9.77e-05	0.00141	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—RHOB—systemic scleroderma	9.56e-05	0.00138	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—HSPG2—systemic scleroderma	9.52e-05	0.00137	CbGpPWpGaD
Celecoxib—CA6—Metabolism—HSPG2—systemic scleroderma	9.52e-05	0.00137	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	9.47e-05	0.00136	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—IL1A—systemic scleroderma	9.46e-05	0.00136	CbGpPWpGaD
Celecoxib—ABCC4—Ectoderm Differentiation—CCL2—systemic scleroderma	9.43e-05	0.00136	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—RHOB—systemic scleroderma	9.24e-05	0.00133	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TGFBI—systemic scleroderma	9.22e-05	0.00133	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—CTLA4—systemic scleroderma	9.04e-05	0.0013	CbGpPWpGaD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	9.02e-05	0.0013	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	8.99e-05	0.00129	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—SELP—systemic scleroderma	8.97e-05	0.00129	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—HSPG2—systemic scleroderma	8.88e-05	0.00128	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—IL1B—systemic scleroderma	8.82e-05	0.00127	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—CSK—systemic scleroderma	8.71e-05	0.00125	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	8.7e-05	0.00125	CbGpPWpGaD
Celecoxib—Nausea—Mometasone—systemic scleroderma	8.64e-05	0.000424	CcSEcCtD
Celecoxib—Anorexia—Lisinopril—systemic scleroderma	8.63e-05	0.000423	CcSEcCtD
Celecoxib—Gastrointestinal pain—Leflunomide—systemic scleroderma	8.61e-05	0.000422	CcSEcCtD
Celecoxib—Weight increased—Prednisone—systemic scleroderma	8.6e-05	0.000422	CcSEcCtD
Celecoxib—ABCC4—Platelet degranulation—TGFB1—systemic scleroderma	8.6e-05	0.00124	CbGpPWpGaD
Celecoxib—Ataxia—Methotrexate—systemic scleroderma	8.59e-05	0.000421	CcSEcCtD
Celecoxib—Constipation—Mycophenolic acid—systemic scleroderma	8.59e-05	0.000421	CcSEcCtD
Celecoxib—Palpitations—Mycophenolate mofetil—systemic scleroderma	8.59e-05	0.000421	CcSEcCtD
Celecoxib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	8.54e-05	0.000419	CcSEcCtD
Celecoxib—MAPK14—Developmental Biology—RHOB—systemic scleroderma	8.53e-05	0.00123	CbGpPWpGaD
Celecoxib—Hyperglycaemia—Prednisone—systemic scleroderma	8.53e-05	0.000418	CcSEcCtD
Celecoxib—MAPK14—Signaling by VEGF—NOS3—systemic scleroderma	8.52e-05	0.00123	CbGpPWpGaD
Celecoxib—Cough—Mycophenolate mofetil—systemic scleroderma	8.48e-05	0.000416	CcSEcCtD
Celecoxib—Dizziness—Captopril—systemic scleroderma	8.45e-05	0.000414	CcSEcCtD
Celecoxib—Liver function test abnormal—Methotrexate—systemic scleroderma	8.44e-05	0.000414	CcSEcCtD
Celecoxib—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	8.39e-05	0.00121	CbGpPWpGaD
Celecoxib—Hypertension—Mycophenolate mofetil—systemic scleroderma	8.39e-05	0.000411	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—RHOB—systemic scleroderma	8.37e-05	0.00121	CbGpPWpGaD
Celecoxib—Urticaria—Leflunomide—systemic scleroderma	8.37e-05	0.00041	CcSEcCtD
Celecoxib—Body temperature increased—Leflunomide—systemic scleroderma	8.33e-05	0.000408	CcSEcCtD
Celecoxib—Abdominal pain—Leflunomide—systemic scleroderma	8.33e-05	0.000408	CcSEcCtD
Celecoxib—Acute coronary syndrome—Prednisone—systemic scleroderma	8.31e-05	0.000407	CcSEcCtD
Celecoxib—Feeling abnormal—Mycophenolic acid—systemic scleroderma	8.28e-05	0.000406	CcSEcCtD
Celecoxib—Chest pain—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000406	CcSEcCtD
Celecoxib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000406	CcSEcCtD
Celecoxib—Myalgia—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000406	CcSEcCtD
Celecoxib—Neuropathy peripheral—Prednisone—systemic scleroderma	8.26e-05	0.000405	CcSEcCtD
Celecoxib—Myocardial infarction—Prednisone—systemic scleroderma	8.26e-05	0.000405	CcSEcCtD
Celecoxib—Breast disorder—Methotrexate—systemic scleroderma	8.26e-05	0.000405	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	8.24e-05	0.000404	CcSEcCtD
Celecoxib—Anxiety—Mycophenolate mofetil—systemic scleroderma	8.24e-05	0.000404	CcSEcCtD
Celecoxib—CA12—Metabolism—HSPG2—systemic scleroderma	8.23e-05	0.00119	CbGpPWpGaD
Celecoxib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	8.23e-05	0.000404	CcSEcCtD
Celecoxib—Hypersensitivity—Azathioprine—systemic scleroderma	8.22e-05	0.000403	CcSEcCtD
Celecoxib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	8.22e-05	0.000403	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	8.21e-05	0.000403	CcSEcCtD
Celecoxib—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	8.19e-05	0.00118	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—ITGAM—systemic scleroderma	8.19e-05	0.00118	CbGpPWpGaD
Celecoxib—Insomnia—Lisinopril—systemic scleroderma	8.19e-05	0.000401	CcSEcCtD
Celecoxib—Paraesthesia—Lisinopril—systemic scleroderma	8.13e-05	0.000398	CcSEcCtD
Celecoxib—Vomiting—Captopril—systemic scleroderma	8.12e-05	0.000398	CcSEcCtD
Celecoxib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	8.09e-05	0.000397	CcSEcCtD
Celecoxib—Dyspnoea—Lisinopril—systemic scleroderma	8.07e-05	0.000396	CcSEcCtD
Celecoxib—Rash—Captopril—systemic scleroderma	8.06e-05	0.000395	CcSEcCtD
Celecoxib—Dermatitis—Captopril—systemic scleroderma	8.05e-05	0.000395	CcSEcCtD
Celecoxib—Somnolence—Lisinopril—systemic scleroderma	8.05e-05	0.000394	CcSEcCtD
Celecoxib—Headache—Captopril—systemic scleroderma	8.01e-05	0.000393	CcSEcCtD
Celecoxib—Confusional state—Mycophenolate mofetil—systemic scleroderma	7.99e-05	0.000392	CcSEcCtD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	7.98e-05	0.00115	CbGpPWpGaD
Celecoxib—Dyspepsia—Lisinopril—systemic scleroderma	7.97e-05	0.000391	CcSEcCtD
Celecoxib—Body temperature increased—Mycophenolic acid—systemic scleroderma	7.94e-05	0.000389	CcSEcCtD
Celecoxib—Abdominal pain—Mycophenolic acid—systemic scleroderma	7.94e-05	0.000389	CcSEcCtD
Celecoxib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	7.93e-05	0.000389	CcSEcCtD
Celecoxib—Oedema—Mycophenolate mofetil—systemic scleroderma	7.93e-05	0.000389	CcSEcCtD
Celecoxib—Infection—Mycophenolate mofetil—systemic scleroderma	7.88e-05	0.000386	CcSEcCtD
Celecoxib—Decreased appetite—Lisinopril—systemic scleroderma	7.87e-05	0.000386	CcSEcCtD
Celecoxib—Eosinophilia—Methotrexate—systemic scleroderma	7.82e-05	0.000383	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	7.81e-05	0.000383	CcSEcCtD
Celecoxib—Fatigue—Lisinopril—systemic scleroderma	7.8e-05	0.000383	CcSEcCtD
Celecoxib—Shock—Mycophenolate mofetil—systemic scleroderma	7.8e-05	0.000383	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	7.8e-05	0.00112	CbGpPWpGaD
Celecoxib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	7.78e-05	0.000381	CcSEcCtD
Celecoxib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	7.76e-05	0.000381	CcSEcCtD
Celecoxib—Hypersensitivity—Leflunomide—systemic scleroderma	7.76e-05	0.00038	CcSEcCtD
Celecoxib—Pancreatitis—Methotrexate—systemic scleroderma	7.74e-05	0.00038	CcSEcCtD
Celecoxib—Constipation—Lisinopril—systemic scleroderma	7.74e-05	0.000379	CcSEcCtD
Celecoxib—Tachycardia—Mycophenolate mofetil—systemic scleroderma	7.74e-05	0.000379	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—CCL2—systemic scleroderma	7.7e-05	0.00111	CbGpPWpGaD
Celecoxib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.000378	CcSEcCtD
Celecoxib—PDPK1—Immune System—CSK—systemic scleroderma	7.69e-05	0.00111	CbGpPWpGaD
Celecoxib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	7.67e-05	0.000376	CcSEcCtD
Celecoxib—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	7.64e-05	0.0011	CbGpPWpGaD
Celecoxib—Diarrhoea—Azathioprine—systemic scleroderma	7.63e-05	0.000374	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—CSK—systemic scleroderma	7.62e-05	0.0011	CbGpPWpGaD
Celecoxib—Haemoglobin—Prednisone—systemic scleroderma	7.6e-05	0.000373	CcSEcCtD
Celecoxib—Nausea—Captopril—systemic scleroderma	7.59e-05	0.000372	CcSEcCtD
Celecoxib—PDPK1—Immune System—IRF5—systemic scleroderma	7.57e-05	0.00109	CbGpPWpGaD
Celecoxib—Haemorrhage—Prednisone—systemic scleroderma	7.57e-05	0.000371	CcSEcCtD
Celecoxib—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	7.56e-05	0.00109	CbGpPWpGaD
Celecoxib—Anorexia—Mycophenolate mofetil—systemic scleroderma	7.56e-05	0.000371	CcSEcCtD
Celecoxib—Asthenia—Leflunomide—systemic scleroderma	7.56e-05	0.000371	CcSEcCtD
Celecoxib—Hallucination—Prednisone—systemic scleroderma	7.53e-05	0.000369	CcSEcCtD
Celecoxib—Pancytopenia—Methotrexate—systemic scleroderma	7.5e-05	0.000368	CcSEcCtD
Celecoxib—Feeling abnormal—Lisinopril—systemic scleroderma	7.46e-05	0.000366	CcSEcCtD
Celecoxib—Pruritus—Leflunomide—systemic scleroderma	7.45e-05	0.000365	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	7.44e-05	0.00107	CbGpPWpGaD
Celecoxib—Connective tissue disorder—Prednisone—systemic scleroderma	7.43e-05	0.000365	CcSEcCtD
Celecoxib—CA14—Metabolism—CTGF—systemic scleroderma	7.4e-05	0.00107	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Lisinopril—systemic scleroderma	7.4e-05	0.000363	CcSEcCtD
Celecoxib—Dysuria—Methotrexate—systemic scleroderma	7.39e-05	0.000362	CcSEcCtD
Celecoxib—Dizziness—Azathioprine—systemic scleroderma	7.37e-05	0.000362	CcSEcCtD
Celecoxib—PDPK1—Disease—HSPG2—systemic scleroderma	7.35e-05	0.00106	CbGpPWpGaD
Celecoxib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	7.34e-05	0.00036	CcSEcCtD
Celecoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	7.24e-05	0.00104	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—ITGAM—systemic scleroderma	7.23e-05	0.00104	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IRF8—systemic scleroderma	7.23e-05	0.00104	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD247—systemic scleroderma	7.23e-05	0.00104	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	7.22e-05	0.000354	CcSEcCtD
Celecoxib—CA5A—Metabolism—CTGF—systemic scleroderma	7.21e-05	0.00104	CbGpPWpGaD
Celecoxib—CA6—Metabolism—CTGF—systemic scleroderma	7.21e-05	0.00104	CbGpPWpGaD
Celecoxib—Photosensitivity reaction—Methotrexate—systemic scleroderma	7.21e-05	0.000354	CcSEcCtD
Celecoxib—Asthenia—Mycophenolic acid—systemic scleroderma	7.21e-05	0.000353	CcSEcCtD
Celecoxib—Diarrhoea—Leflunomide—systemic scleroderma	7.21e-05	0.000353	CcSEcCtD
Celecoxib—Urticaria—Lisinopril—systemic scleroderma	7.19e-05	0.000353	CcSEcCtD
Celecoxib—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	7.18e-05	0.00103	CbGpPWpGaD
Celecoxib—Insomnia—Mycophenolate mofetil—systemic scleroderma	7.17e-05	0.000352	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—ITGAM—systemic scleroderma	7.17e-05	0.00103	CbGpPWpGaD
Celecoxib—Body temperature increased—Lisinopril—systemic scleroderma	7.15e-05	0.000351	CcSEcCtD
Celecoxib—Abdominal pain—Lisinopril—systemic scleroderma	7.15e-05	0.000351	CcSEcCtD
Celecoxib—MAPK14—Cellular responses to stress—IL1A—systemic scleroderma	7.15e-05	0.00103	CbGpPWpGaD
Celecoxib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	7.12e-05	0.000349	CcSEcCtD
Celecoxib—Pruritus—Mycophenolic acid—systemic scleroderma	7.11e-05	0.000349	CcSEcCtD
Celecoxib—PDPK1—Disease—CSK—systemic scleroderma	7.1e-05	0.00102	CbGpPWpGaD
Celecoxib—Vomiting—Azathioprine—systemic scleroderma	7.09e-05	0.000348	CcSEcCtD
Celecoxib—Pneumonia—Methotrexate—systemic scleroderma	7.08e-05	0.000347	CcSEcCtD
Celecoxib—Eye disorder—Prednisone—systemic scleroderma	7.07e-05	0.000347	CcSEcCtD
Celecoxib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	7.07e-05	0.000347	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—SMAD7—systemic scleroderma	7.06e-05	0.00102	CbGpPWpGaD
Celecoxib—Somnolence—Mycophenolate mofetil—systemic scleroderma	7.05e-05	0.000346	CcSEcCtD
Celecoxib—Infestation—Methotrexate—systemic scleroderma	7.04e-05	0.000345	CcSEcCtD
Celecoxib—Infestation NOS—Methotrexate—systemic scleroderma	7.04e-05	0.000345	CcSEcCtD
Celecoxib—Rash—Azathioprine—systemic scleroderma	7.03e-05	0.000345	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—CD40LG—systemic scleroderma	7.03e-05	0.00101	CbGpPWpGaD
Celecoxib—Dermatitis—Azathioprine—systemic scleroderma	7.03e-05	0.000344	CcSEcCtD
Celecoxib—Flushing—Prednisone—systemic scleroderma	7.02e-05	0.000344	CcSEcCtD
Celecoxib—Headache—Azathioprine—systemic scleroderma	6.99e-05	0.000343	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	6.98e-05	0.000342	CcSEcCtD
Celecoxib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.98e-05	0.000342	CcSEcCtD
Celecoxib—Dizziness—Leflunomide—systemic scleroderma	6.96e-05	0.000342	CcSEcCtD
Celecoxib—PDPK1—Hemostasis—MMP1—systemic scleroderma	6.91e-05	0.000995	CbGpPWpGaD
Celecoxib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	6.89e-05	0.000338	CcSEcCtD
Celecoxib—Diarrhoea—Mycophenolic acid—systemic scleroderma	6.87e-05	0.000337	CcSEcCtD
Celecoxib—Stomatitis—Methotrexate—systemic scleroderma	6.86e-05	0.000337	CcSEcCtD
Celecoxib—Angiopathy—Prednisone—systemic scleroderma	6.86e-05	0.000337	CcSEcCtD
Celecoxib—MAPK14—TCR Signaling Pathway—TGFB1—systemic scleroderma	6.85e-05	0.000987	CbGpPWpGaD
Celecoxib—Conjunctivitis—Methotrexate—systemic scleroderma	6.85e-05	0.000336	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	6.85e-05	0.000336	CcSEcCtD
Celecoxib—Immune system disorder—Prednisone—systemic scleroderma	6.83e-05	0.000335	CcSEcCtD
Celecoxib—Constipation—Mycophenolate mofetil—systemic scleroderma	6.78e-05	0.000332	CcSEcCtD
Celecoxib—PDPK1—Immune System—TNFAIP3—systemic scleroderma	6.77e-05	0.000975	CbGpPWpGaD
Celecoxib—Arrhythmia—Prednisone—systemic scleroderma	6.76e-05	0.000331	CcSEcCtD
Celecoxib—MAPK14—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	6.73e-05	0.00097	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—CTGF—systemic scleroderma	6.73e-05	0.00097	CbGpPWpGaD
Celecoxib—Haematuria—Methotrexate—systemic scleroderma	6.72e-05	0.000329	CcSEcCtD
Celecoxib—Vomiting—Leflunomide—systemic scleroderma	6.7e-05	0.000328	CcSEcCtD
Celecoxib—PDPK1—Immune System—BLK—systemic scleroderma	6.69e-05	0.000964	CbGpPWpGaD
Celecoxib—Alopecia—Prednisone—systemic scleroderma	6.69e-05	0.000328	CcSEcCtD
Celecoxib—PDPK1—Disease—CD247—systemic scleroderma	6.68e-05	0.000962	CbGpPWpGaD
Celecoxib—Hypersensitivity—Lisinopril—systemic scleroderma	6.67e-05	0.000327	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—systemic scleroderma	6.66e-05	0.000327	CcSEcCtD
Celecoxib—Dizziness—Mycophenolic acid—systemic scleroderma	6.64e-05	0.000326	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—systemic scleroderma	6.64e-05	0.000326	CcSEcCtD
Celecoxib—Rash—Leflunomide—systemic scleroderma	6.64e-05	0.000326	CcSEcCtD
Celecoxib—Dermatitis—Leflunomide—systemic scleroderma	6.63e-05	0.000325	CcSEcCtD
Celecoxib—Mental disorder—Prednisone—systemic scleroderma	6.63e-05	0.000325	CcSEcCtD
Celecoxib—Nausea—Azathioprine—systemic scleroderma	6.62e-05	0.000325	CcSEcCtD
Celecoxib—Headache—Leflunomide—systemic scleroderma	6.6e-05	0.000324	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—systemic scleroderma	6.57e-05	0.000322	CcSEcCtD
Celecoxib—CA4—Metabolism—HSPG2—systemic scleroderma	6.56e-05	0.000945	CbGpPWpGaD
Celecoxib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	6.53e-05	0.00032	CcSEcCtD
Celecoxib—Asthenia—Lisinopril—systemic scleroderma	6.49e-05	0.000318	CcSEcCtD
Celecoxib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	6.48e-05	0.000318	CcSEcCtD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	6.48e-05	0.000933	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—ITGAM—systemic scleroderma	6.45e-05	0.000929	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CD247—systemic scleroderma	6.45e-05	0.000929	CbGpPWpGaD
Celecoxib—PDPK1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	6.43e-05	0.000926	CbGpPWpGaD
Celecoxib—Pruritus—Lisinopril—systemic scleroderma	6.4e-05	0.000314	CcSEcCtD
Celecoxib—Vomiting—Mycophenolic acid—systemic scleroderma	6.39e-05	0.000313	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—systemic scleroderma	6.35e-05	0.000312	CcSEcCtD
Celecoxib—Rash—Mycophenolic acid—systemic scleroderma	6.33e-05	0.000311	CcSEcCtD
Celecoxib—Dermatitis—Mycophenolic acid—systemic scleroderma	6.33e-05	0.00031	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—systemic scleroderma	6.32e-05	0.00031	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—systemic scleroderma	6.32e-05	0.00031	CcSEcCtD
Celecoxib—Urticaria—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000309	CcSEcCtD
Celecoxib—Headache—Mycophenolic acid—systemic scleroderma	6.29e-05	0.000309	CcSEcCtD
Celecoxib—CA2—Metabolism—HSPG2—systemic scleroderma	6.29e-05	0.000906	CbGpPWpGaD
Celecoxib—Pharyngitis—Methotrexate—systemic scleroderma	6.27e-05	0.000308	CcSEcCtD
Celecoxib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	6.27e-05	0.000307	CcSEcCtD
Celecoxib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	6.27e-05	0.000307	CcSEcCtD
Celecoxib—Nausea—Leflunomide—systemic scleroderma	6.26e-05	0.000307	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—systemic scleroderma	6.24e-05	0.000306	CcSEcCtD
Celecoxib—CA12—Metabolism—CTGF—systemic scleroderma	6.24e-05	0.000898	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	6.23e-05	0.000897	CbGpPWpGaD
Celecoxib—Vision blurred—Prednisone—systemic scleroderma	6.21e-05	0.000304	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—systemic scleroderma	6.2e-05	0.000304	CcSEcCtD
Celecoxib—Diarrhoea—Lisinopril—systemic scleroderma	6.19e-05	0.000304	CcSEcCtD
Celecoxib—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	6.12e-05	0.000881	CbGpPWpGaD
Celecoxib—Anaemia—Prednisone—systemic scleroderma	6.09e-05	0.000298	CcSEcCtD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	6.06e-05	0.000872	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—TNFAIP3—systemic scleroderma	6.04e-05	0.00087	CbGpPWpGaD
Celecoxib—Angioedema—Prednisone—systemic scleroderma	6.02e-05	0.000295	CcSEcCtD
Celecoxib—Dizziness—Lisinopril—systemic scleroderma	5.98e-05	0.000293	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	5.98e-05	0.000861	CbGpPWpGaD
Celecoxib—Erythema multiforme—Methotrexate—systemic scleroderma	5.98e-05	0.000293	CcSEcCtD
Celecoxib—Nausea—Mycophenolic acid—systemic scleroderma	5.97e-05	0.000293	CcSEcCtD
Celecoxib—Vertigo—Prednisone—systemic scleroderma	5.92e-05	0.00029	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—systemic scleroderma	5.91e-05	0.00029	CcSEcCtD
Celecoxib—Syncope—Prednisone—systemic scleroderma	5.91e-05	0.00029	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—systemic scleroderma	5.89e-05	0.000289	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—systemic scleroderma	5.87e-05	0.000288	CcSEcCtD
Celecoxib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.84e-05	0.000286	CcSEcCtD
Celecoxib—ALB—Folate Metabolism—IL1B—systemic scleroderma	5.84e-05	0.000841	CbGpPWpGaD
Celecoxib—Loss of consciousness—Prednisone—systemic scleroderma	5.79e-05	0.000284	CcSEcCtD
Celecoxib—Vomiting—Lisinopril—systemic scleroderma	5.75e-05	0.000282	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—systemic scleroderma	5.74e-05	0.000281	CcSEcCtD
Celecoxib—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	5.74e-05	0.000826	CbGpPWpGaD
Celecoxib—Immune system disorder—Methotrexate—systemic scleroderma	5.71e-05	0.00028	CcSEcCtD
Celecoxib—Rash—Lisinopril—systemic scleroderma	5.71e-05	0.00028	CcSEcCtD
Celecoxib—Dermatitis—Lisinopril—systemic scleroderma	5.7e-05	0.00028	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—systemic scleroderma	5.7e-05	0.000279	CcSEcCtD
Celecoxib—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.69e-05	0.000279	CcSEcCtD
Celecoxib—Hypertension—Prednisone—systemic scleroderma	5.69e-05	0.000279	CcSEcCtD
Celecoxib—Headache—Lisinopril—systemic scleroderma	5.67e-05	0.000278	CcSEcCtD
Celecoxib—MAPK14—Gene Expression—SMAD7—systemic scleroderma	5.64e-05	0.000812	CbGpPWpGaD
Celecoxib—Pruritus—Mycophenolate mofetil—systemic scleroderma	5.61e-05	0.000275	CcSEcCtD
Celecoxib—Myalgia—Prednisone—systemic scleroderma	5.61e-05	0.000275	CcSEcCtD
Celecoxib—Arthralgia—Prednisone—systemic scleroderma	5.61e-05	0.000275	CcSEcCtD
Celecoxib—Anxiety—Prednisone—systemic scleroderma	5.59e-05	0.000274	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—systemic scleroderma	5.59e-05	0.000274	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.57e-05	0.000273	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—systemic scleroderma	5.54e-05	0.000272	CcSEcCtD
Celecoxib—PDPK1—Immune System—CTLA4—systemic scleroderma	5.48e-05	0.000789	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—RHOB—systemic scleroderma	5.46e-05	0.000786	CbGpPWpGaD
Celecoxib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000266	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—systemic scleroderma	5.39e-05	0.000264	CcSEcCtD
Celecoxib—Nausea—Lisinopril—systemic scleroderma	5.38e-05	0.000264	CcSEcCtD
Celecoxib—Oedema—Prednisone—systemic scleroderma	5.37e-05	0.000264	CcSEcCtD
Celecoxib—Anaphylactic shock—Prednisone—systemic scleroderma	5.37e-05	0.000264	CcSEcCtD
Celecoxib—MAPK14—MAPK Signaling Pathway—IL1B—systemic scleroderma	5.35e-05	0.000771	CbGpPWpGaD
Celecoxib—Infection—Prednisone—systemic scleroderma	5.34e-05	0.000262	CcSEcCtD
Celecoxib—Back pain—Methotrexate—systemic scleroderma	5.32e-05	0.000261	CcSEcCtD
Celecoxib—ABCC4—NRF2 pathway—TGFB1—systemic scleroderma	5.32e-05	0.000765	CbGpPWpGaD
Celecoxib—CA9—Metabolism—HSPG2—systemic scleroderma	5.3e-05	0.000764	CbGpPWpGaD
Celecoxib—Shock—Prednisone—systemic scleroderma	5.29e-05	0.000259	CcSEcCtD
Celecoxib—Nervous system disorder—Prednisone—systemic scleroderma	5.27e-05	0.000258	CcSEcCtD
Celecoxib—Tachycardia—Prednisone—systemic scleroderma	5.25e-05	0.000257	CcSEcCtD
Celecoxib—MAPK14—Gene Expression—TNFSF13—systemic scleroderma	5.24e-05	0.000755	CbGpPWpGaD
Celecoxib—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.24e-05	0.000257	CcSEcCtD
Celecoxib—Skin disorder—Prednisone—systemic scleroderma	5.22e-05	0.000256	CcSEcCtD
Celecoxib—PDPK1—GPCR downstream signaling—EDN1—systemic scleroderma	5.2e-05	0.000748	CbGpPWpGaD
Celecoxib—Hyperhidrosis—Prednisone—systemic scleroderma	5.2e-05	0.000255	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—systemic scleroderma	5.19e-05	0.000254	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—HSPG2—systemic scleroderma	5.15e-05	0.000742	CbGpPWpGaD
Celecoxib—Anorexia—Prednisone—systemic scleroderma	5.12e-05	0.000251	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—systemic scleroderma	5.09e-05	0.000249	CcSEcCtD
Celecoxib—MAPK14—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	5.04e-05	0.000726	CbGpPWpGaD
Celecoxib—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.04e-05	0.000247	CcSEcCtD
Celecoxib—PDPK1—Hemostasis—NOS3—systemic scleroderma	5.01e-05	0.000722	CbGpPWpGaD
Celecoxib—Rash—Mycophenolate mofetil—systemic scleroderma	5e-05	0.000245	CcSEcCtD
Celecoxib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.99e-05	0.000245	CcSEcCtD
Celecoxib—CA4—Metabolism—CTGF—systemic scleroderma	4.97e-05	0.000716	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CSK—systemic scleroderma	4.97e-05	0.000716	CbGpPWpGaD
Celecoxib—Headache—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000244	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—systemic scleroderma	4.94e-05	0.000242	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—systemic scleroderma	4.93e-05	0.000242	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.9e-05	0.00024	CcSEcCtD
Celecoxib—Insomnia—Prednisone—systemic scleroderma	4.86e-05	0.000238	CcSEcCtD
Celecoxib—Paraesthesia—Prednisone—systemic scleroderma	4.83e-05	0.000237	CcSEcCtD
Celecoxib—Cough—Methotrexate—systemic scleroderma	4.8e-05	0.000235	CcSEcCtD
Celecoxib—CA2—Metabolism—CTGF—systemic scleroderma	4.77e-05	0.000687	CbGpPWpGaD
Celecoxib—Dyspepsia—Prednisone—systemic scleroderma	4.73e-05	0.000232	CcSEcCtD
Celecoxib—PDPK1—Signaling by GPCR—EDN1—systemic scleroderma	4.72e-05	0.00068	CbGpPWpGaD
Celecoxib—Nausea—Mycophenolate mofetil—systemic scleroderma	4.71e-05	0.000231	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—systemic scleroderma	4.69e-05	0.00023	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—systemic scleroderma	4.69e-05	0.00023	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—systemic scleroderma	4.69e-05	0.00023	CcSEcCtD
Celecoxib—Decreased appetite—Prednisone—systemic scleroderma	4.67e-05	0.000229	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.65e-05	0.000228	CcSEcCtD
Celecoxib—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	4.64e-05	0.000668	CbGpPWpGaD
Celecoxib—Fatigue—Prednisone—systemic scleroderma	4.63e-05	0.000227	CcSEcCtD
Celecoxib—ALB—Hemostasis—SELP—systemic scleroderma	4.63e-05	0.000667	CbGpPWpGaD
Celecoxib—Constipation—Prednisone—systemic scleroderma	4.6e-05	0.000225	CcSEcCtD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.59e-05	0.000661	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	4.54e-05	0.000653	CbGpPWpGaD
Celecoxib—Confusional state—Methotrexate—systemic scleroderma	4.53e-05	0.000222	CcSEcCtD
Celecoxib—PDPK1—Immune System—HLA-DQB1—systemic scleroderma	4.51e-05	0.00065	CbGpPWpGaD
Celecoxib—Anaphylactic shock—Methotrexate—systemic scleroderma	4.49e-05	0.00022	CcSEcCtD
Celecoxib—Infection—Methotrexate—systemic scleroderma	4.46e-05	0.000219	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisone—systemic scleroderma	4.43e-05	0.000217	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—systemic scleroderma	4.41e-05	0.000216	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—systemic scleroderma	4.4e-05	0.000216	CcSEcCtD
Celecoxib—Gastrointestinal pain—Prednisone—systemic scleroderma	4.4e-05	0.000216	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—systemic scleroderma	4.36e-05	0.000214	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—systemic scleroderma	4.34e-05	0.000213	CcSEcCtD
Celecoxib—ALB—Hemostasis—RHOB—systemic scleroderma	4.33e-05	0.000623	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL1A—systemic scleroderma	4.29e-05	0.000617	CbGpPWpGaD
Celecoxib—Anorexia—Methotrexate—systemic scleroderma	4.28e-05	0.00021	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	4.28e-05	0.000616	CbGpPWpGaD
Celecoxib—Urticaria—Prednisone—systemic scleroderma	4.27e-05	0.000209	CcSEcCtD
Celecoxib—PDPK1—Immune System—CD40LG—systemic scleroderma	4.26e-05	0.000614	CbGpPWpGaD
Celecoxib—Body temperature increased—Prednisone—systemic scleroderma	4.25e-05	0.000208	CcSEcCtD
Celecoxib—Abdominal pain—Prednisone—systemic scleroderma	4.25e-05	0.000208	CcSEcCtD
Celecoxib—MAPK14—MAPK Signaling Pathway—TGFB1—systemic scleroderma	4.16e-05	0.000599	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—MMP1—systemic scleroderma	4.1e-05	0.000591	CbGpPWpGaD
Celecoxib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.09e-05	0.000201	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—systemic scleroderma	4.06e-05	0.000199	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—systemic scleroderma	4.03e-05	0.000198	CcSEcCtD
Celecoxib—CA9—Metabolism—CTGF—systemic scleroderma	4.02e-05	0.000579	CbGpPWpGaD
Celecoxib—Dyspnoea—Methotrexate—systemic scleroderma	4e-05	0.000196	CcSEcCtD
Celecoxib—MAPK14—Immune System—CSK—systemic scleroderma	4e-05	0.000576	CbGpPWpGaD
Celecoxib—Somnolence—Methotrexate—systemic scleroderma	3.99e-05	0.000196	CcSEcCtD
Celecoxib—Hypersensitivity—Prednisone—systemic scleroderma	3.96e-05	0.000194	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—systemic scleroderma	3.95e-05	0.000194	CcSEcCtD
Celecoxib—ALB—Hemostasis—CSK—systemic scleroderma	3.94e-05	0.000567	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IRF5—systemic scleroderma	3.93e-05	0.000566	CbGpPWpGaD
Celecoxib—Decreased appetite—Methotrexate—systemic scleroderma	3.9e-05	0.000191	CcSEcCtD
Celecoxib—ALB—Platelet degranulation—TGFB1—systemic scleroderma	3.89e-05	0.000561	CbGpPWpGaD
Celecoxib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.88e-05	0.00019	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—systemic scleroderma	3.87e-05	0.00019	CcSEcCtD
Celecoxib—Asthenia—Prednisone—systemic scleroderma	3.86e-05	0.000189	CcSEcCtD
Celecoxib—ABCC4—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.82e-05	0.000549	CbGpPWpGaD
Celecoxib—Pruritus—Prednisone—systemic scleroderma	3.8e-05	0.000186	CcSEcCtD
Celecoxib—MAPK14—Immune System—CD247—systemic scleroderma	3.76e-05	0.000541	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IRF8—systemic scleroderma	3.76e-05	0.000541	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ITGAM—systemic scleroderma	3.76e-05	0.000541	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.75e-05	0.000541	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.71e-05	0.000535	CbGpPWpGaD
Celecoxib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	3.71e-05	0.000534	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—ITGAM—systemic scleroderma	3.7e-05	0.000533	CbGpPWpGaD
Celecoxib—Feeling abnormal—Methotrexate—systemic scleroderma	3.7e-05	0.000182	CcSEcCtD
Celecoxib—Diarrhoea—Prednisone—systemic scleroderma	3.68e-05	0.00018	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.67e-05	0.00018	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—SMAD7—systemic scleroderma	3.67e-05	0.000528	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—MMP1—systemic scleroderma	3.59e-05	0.000517	CbGpPWpGaD
Celecoxib—Urticaria—Methotrexate—systemic scleroderma	3.57e-05	0.000175	CcSEcCtD
Celecoxib—Dizziness—Prednisone—systemic scleroderma	3.55e-05	0.000174	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—systemic scleroderma	3.55e-05	0.000174	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—systemic scleroderma	3.55e-05	0.000174	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	3.53e-05	0.000508	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TNFAIP3—systemic scleroderma	3.52e-05	0.000507	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.48e-05	0.000501	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—BLK—systemic scleroderma	3.48e-05	0.000501	CbGpPWpGaD
Celecoxib—Vomiting—Prednisone—systemic scleroderma	3.42e-05	0.000168	CcSEcCtD
Celecoxib—Rash—Prednisone—systemic scleroderma	3.39e-05	0.000166	CcSEcCtD
Celecoxib—Dermatitis—Prednisone—systemic scleroderma	3.39e-05	0.000166	CcSEcCtD
Celecoxib—Headache—Prednisone—systemic scleroderma	3.37e-05	0.000165	CcSEcCtD
Celecoxib—PTGS2—Disease—SMAD7—systemic scleroderma	3.35e-05	0.000482	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.34e-05	0.000481	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—TGFB1—systemic scleroderma	3.31e-05	0.000477	CbGpPWpGaD
Celecoxib—Hypersensitivity—Methotrexate—systemic scleroderma	3.31e-05	0.000162	CcSEcCtD
Celecoxib—PDPK1—Signaling by GPCR—CCL2—systemic scleroderma	3.23e-05	0.000465	CbGpPWpGaD
Celecoxib—Asthenia—Methotrexate—systemic scleroderma	3.22e-05	0.000158	CcSEcCtD
Celecoxib—CA14—Metabolism—NOS3—systemic scleroderma	3.22e-05	0.000464	CbGpPWpGaD
Celecoxib—Nausea—Prednisone—systemic scleroderma	3.19e-05	0.000157	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—systemic scleroderma	3.18e-05	0.000156	CcSEcCtD
Celecoxib—CA6—Metabolism—NOS3—systemic scleroderma	3.14e-05	0.000452	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—NOS3—systemic scleroderma	3.14e-05	0.000452	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—CTGF—systemic scleroderma	3.12e-05	0.000449	CbGpPWpGaD
Celecoxib—Diarrhoea—Methotrexate—systemic scleroderma	3.07e-05	0.000151	CcSEcCtD
Celecoxib—PTGS2—Disease—TGFBI—systemic scleroderma	3.06e-05	0.000441	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.04e-05	0.000438	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—NOS3—systemic scleroderma	2.97e-05	0.000428	CbGpPWpGaD
Celecoxib—Dizziness—Methotrexate—systemic scleroderma	2.97e-05	0.000146	CcSEcCtD
Celecoxib—CA5B—Metabolism—NOS3—systemic scleroderma	2.93e-05	0.000422	CbGpPWpGaD
Celecoxib—Vomiting—Methotrexate—systemic scleroderma	2.86e-05	0.00014	CcSEcCtD
Celecoxib—MAPK14—Immune System—CTLA4—systemic scleroderma	2.85e-05	0.00041	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RHOB—systemic scleroderma	2.84e-05	0.000409	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MMP2—systemic scleroderma	2.83e-05	0.000408	CbGpPWpGaD
Celecoxib—Rash—Methotrexate—systemic scleroderma	2.83e-05	0.000139	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—systemic scleroderma	2.83e-05	0.000139	CcSEcCtD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.81e-05	0.000405	CbGpPWpGaD
Celecoxib—Headache—Methotrexate—systemic scleroderma	2.81e-05	0.000138	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—EDN1—systemic scleroderma	2.79e-05	0.000401	CbGpPWpGaD
Celecoxib—CA12—Metabolism—NOS3—systemic scleroderma	2.72e-05	0.000391	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HSPG2—systemic scleroderma	2.68e-05	0.000385	CbGpPWpGaD
Celecoxib—Nausea—Methotrexate—systemic scleroderma	2.67e-05	0.000131	CcSEcCtD
Celecoxib—MAPK14—Hemostasis—NOS3—systemic scleroderma	2.6e-05	0.000375	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CSK—systemic scleroderma	2.58e-05	0.000372	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HSPG2—systemic scleroderma	2.44e-05	0.000352	CbGpPWpGaD
Celecoxib—PDPK1—Disease—NOS3—systemic scleroderma	2.43e-05	0.000349	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.4e-05	0.000345	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CSK—systemic scleroderma	2.36e-05	0.00034	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DQB1—systemic scleroderma	2.35e-05	0.000338	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.3e-05	0.000332	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL1B—systemic scleroderma	2.24e-05	0.000322	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1A—systemic scleroderma	2.23e-05	0.000321	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD247—systemic scleroderma	2.22e-05	0.000319	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD40LG—systemic scleroderma	2.21e-05	0.000319	CbGpPWpGaD
Celecoxib—CA4—Metabolism—NOS3—systemic scleroderma	2.17e-05	0.000312	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MMP9—systemic scleroderma	2.13e-05	0.000307	CbGpPWpGaD
Celecoxib—CA2—Metabolism—NOS3—systemic scleroderma	2.08e-05	0.000299	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—HSPG2—systemic scleroderma	2.04e-05	0.000294	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TGFB1—systemic scleroderma	1.97e-05	0.000283	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL2—systemic scleroderma	1.91e-05	0.000274	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MMP1—systemic scleroderma	1.86e-05	0.000267	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TGFB1—systemic scleroderma	1.76e-05	0.000253	CbGpPWpGaD
Celecoxib—CA9—Metabolism—NOS3—systemic scleroderma	1.75e-05	0.000252	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.73e-05	0.000249	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TGFB1—systemic scleroderma	1.72e-05	0.000248	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NOS3—systemic scleroderma	1.7e-05	0.000245	CbGpPWpGaD
Celecoxib—ALB—Metabolism—HSPG2—systemic scleroderma	1.65e-05	0.000238	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TGFB1—systemic scleroderma	1.6e-05	0.000231	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CTGF—systemic scleroderma	1.55e-05	0.000223	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EDN1—systemic scleroderma	1.45e-05	0.000209	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.37e-05	0.000197	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP9—systemic scleroderma	1.36e-05	0.000196	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.35e-05	0.000195	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NOS3—systemic scleroderma	1.35e-05	0.000194	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CTGF—systemic scleroderma	1.25e-05	0.000181	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1B—systemic scleroderma	1.16e-05	0.000167	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TGFB1—systemic scleroderma	1.12e-05	0.000162	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.03e-05	0.000149	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.03e-05	0.000148	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL2—systemic scleroderma	9.9e-06	0.000143	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	8.93e-06	0.000129	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TGFB1—systemic scleroderma	8.9e-06	0.000128	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOS3—systemic scleroderma	8.83e-06	0.000127	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOS3—systemic scleroderma	8.05e-06	0.000116	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—systemic scleroderma	7.08e-06	0.000102	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CTGF—systemic scleroderma	6.77e-06	9.75e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—NOS3—systemic scleroderma	6.74e-06	9.71e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFB1—systemic scleroderma	5.84e-06	8.41e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NOS3—systemic scleroderma	5.46e-06	7.86e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFB1—systemic scleroderma	5.32e-06	7.67e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NOS3—systemic scleroderma	4.51e-06	6.49e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NOS3—systemic scleroderma	4.47e-06	6.43e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.95e-06	4.24e-05	CbGpPWpGaD
